News | August 09, 2023
Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
States advised to undertake mock drills to ensure operational readiness of Hospital Infrastructure including Oxygen Cylinders, PSA plants, ventilators and human resources
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
